Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

National guideline development and adaptation, Egypt.

Bulletin of the World Health Organization·2026
Same author

Persistent physical symptoms not explained by structural abnormalities or disease processes: a primary care approach to promote recovery.

Scandinavian journal of primary health care·2026
Same author

Expert stakeholders on the role of qualitative research in World Health Organisation guidelines.

Health policy and planning·2026
Same author

Experiences of Female Rugby Union Players and Practitioners in Rehabilitation Following a Shoulder Injury.

Sports (Basel, Switzerland)·2025
Same author

Patients with severe ME/CFS need hope and expert multidisciplinary care.

BMJ (Clinical research ed.)·2025
Same author

Longitudinal study of five seasons of upper limb injuries in training and matches in elite female rugby union at club and national team level.

BMJ open sport & exercise medicine·2025
Same journal

Rheumatoid arthritis: previously untreated early disease.

BMJ clinical evidence·2016
Same journal

Diabetic retinopathy: intravitreal vascular endothelial growth factor inhibitors for diabetic macular oedema.

BMJ clinical evidence·2016
Same journal

Subarachnoid haemorrhage (spontaneous aneurysmal).

BMJ clinical evidence·2016
Same journal

Malaria: fluid therapy in severe disease.

BMJ clinical evidence·2016
Same journal

Age-related macular degeneration: anti-vascular endothelial growth factor treatment.

BMJ clinical evidence·2016
Same journal

MRSA: treating people with infection.

BMJ clinical evidence·2016
See all related articles

Related Experiment Video

Updated: Jun 23, 2026

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
07:21

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment

Published on: June 23, 2019

Tuberculosis (HIV-negative people).

Lilia E Ziganshina1, Paul Garner

  • 1Health Action International, Amsterdam, The Netherlands.

BMJ Clinical Evidence
|May 19, 2009
PubMed
Summary
This summary is machine-generated.

This review examines tuberculosis (TB) treatment and prevention strategies for individuals without HIV. It found various interventions, including drug regimens and adherence support, effective for TB management.

More Related Videos

Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients
13:50

Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients

Published on: June 11, 2011

Related Experiment Videos

Last Updated: Jun 23, 2026

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
07:21

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment

Published on: June 23, 2019

Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients
13:50

Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients

Published on: June 11, 2011

Area of Science:

  • Public Health
  • Infectious Diseases
  • Clinical Medicine

Background:

  • Tuberculosis (TB) remains a significant global health challenge, with a high prevalence of latent and active cases.
  • In 2004, over 14 million people had active TB, resulting in approximately 1.7 million deaths.
  • The majority of new TB cases in 2004 were concentrated in Africa, South-East Asia, and Western Pacific regions.

Purpose of the Study:

  • To systematically review interventions for preventing tuberculosis in high-risk individuals without HIV.
  • To evaluate the effectiveness of different drug regimens for newly diagnosed and multidrug-resistant pulmonary tuberculosis in non-HIV individuals.
  • To assess interventions that improve treatment adherence and explore the role of low-level laser therapy in TB management.

Main Methods:

  • A systematic review of 31 studies, including systematic reviews, randomized controlled trials (RCTs), and observational studies.
  • Searches conducted across major databases (Medline, Embase, Cochrane Library) up to July 2008.
  • Inclusion of harms alerts from regulatory agencies like the FDA and MHRA.

Main Results:

  • Evidence was evaluated using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system.
  • The review identified 31 relevant studies meeting the inclusion criteria.
  • Data on the effectiveness and safety of various interventions were compiled.

Conclusions:

  • The review presents findings on the effectiveness and safety of numerous TB interventions.
  • Key interventions discussed include adding pyrazinamide or rifampicin to chemotherapy, different treatment durations (e.g., <6 months, daily vs. intermittent), and direct observation strategies.
  • The review also covers isoniazid, rifampicin plus isoniazid regimens, low-level laser therapy, and adherence support mechanisms.